RetaMaps

Arturo Garcia, MD

Arturo Garcia, MD · 481 Plumas Boulevard · Yuba City, CA 95991

4.8· 22 Google reviews

Listing updated October 2, 2026

Quick facts

Address
481 Plumas Boulevard, Yuba City, CA 95991
Phone
(530) 749-2409
Website
doctors.adventisthealth.org
Telehealth
Yes
FDA-approved GLP-1 medications listed
None listed on its website
Accepting new patients (per website)
Yes
Accepts insurance (per website)
Yes
Google rating
★4.8 from 22 reviews
Patient sentiment
95% positive, 5% negative (22 reviews analyzed)
Most praised
Feeling listened to (8 reviews)
Most common complaint
None recurring
Retatrutide
Not yet available anywhere — investigational, not FDA-approved
Listing last updated
October 2, 2026
Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Arturo Garcia, MD, is a physician in Yuba City, California, whose listing includes hormone care and telehealth visits. The listing points to Adventist Health's provider finder, and no further practice details were available. On Google the listing has a 4.8-star rating across 22 reviews dating to 2017, with 2 in the past year; reviewers mention a caring approach (8), the staff (7) and knowledge (6).

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 22 reviews
2
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-28. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.8 across 22 Google reviews. Of the 22 reviews we analyzed, 21 (95%) are positive (4–5★) and 1 (5%) are negative (1–2★).

What patients like

  • Feeling listened to8 reviews
  • Friendly, helpful staff7 reviews
  • Knowledgeable, professional providers6 reviews

Common complaints

Very few complaints — only 1 negative review, with no recurring theme.

5★
21
4★
0
3★
0
2★
0
1★
1

Most recent Google reviews

Tamara A.★★★★★2026-09-28

Thank you Dr Garcia.... I'm on my way to a new life because of u and your team

Margaret L.★★★★★2025-12-10

He listened and explained everything . I like him

doraemon c.★★★★★2025-01-17

Amazing and professional doctors. Thank you Dr Garcia for surgery removed my gallbladder. Dr Garcia very professional and kind doctor. God bless you, your family and your team.

Janney R.★★★★★2024-08-17

I want to thank Dr. García.por aver cambiando mi vida con la operación de bajar de peso y le doy Gracias a dios primero y al doctor por ser un buen Sirugano y gran persona por cambiar vidas y volver a la salud normal Gracias doctor garcía bendiciones

Patty Z.★★★★★2024-05-20

Me canvio mi vida exelente doctor y su personal exelente vendiciones 🙏

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Clinicians

  • Arturo Garcia, MD

Nearby providers in Yuba City

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs